Investor Centre

Boehringer Ingelheim is initiating Phase 2a study for the development of a new treatment for diabetic retinopathy – a leading cause of vision-loss

• Diabetic retinopathy (DR) is the second severe metabolic complication on top of non-alcoholic steatohepatitis (NASH) to be investigated for BI 1467335 (formerly known as PXS-4728A), which was acquired from Pharmaxis in 2015
• Pharmaxis will receive €10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.
• Boehringer Ingelheim’s holistic cardio metabolism R&D strategy reaches from risk factors, like obesity to complications, like NASH and DR

INGELHEIM, Germany and SYDNEY, Australia – 7 September 2017 – Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN (Randomized study of Orally administered BI 1467335 in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema).[1] This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH. BI 1467335 is an oral inhibitor of amine oxidase, copper containing 3 (AOC3).